Akebia Therap (AKBA.US) Stock Community - Hot Topic Discussions

Quote List Quote List

Event Tracking

Dec1

Akebia Therapeutics Establishes Rare Kidney Disease Pipeline and Initiates Drug Trials

13:21

Nov11

BTIG Analyst Maintains Buy Rating for Akebia Therapeutics

11:57

Nov10

Akebia Therap released FY2025 Q3 earnings on November 10 Pre-Market EST, actual revenue USD 58.77 M (forecast USD 56.42 M), actual EPS USD 0.0019 (forecast USD -0.015)

14:30

Akebia Therap released FY2025 9 Months Earnings on November 10 Pre-Market EST, with actual revenue of USD 178.57 M and EPS of USD 0.0288

14:30

Nov3

Akebia Therapeutics to Release FY2025 Q3 Earnings on November 10, Pre-Market EST; Forecast Revenue USD 56.06 M, EPS USD -0.016

00:18

Oct29

Akebia Therapeutics Inc. Abandons Pursuit of Broad Label for Vafseo

18:22

Schedules & Filings

Schedules

Filings

Nov10

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 58.77 M, Net Income 540 K, EPS 0.0019

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 62.47 M, Net Income 247 K, EPS 0.0009

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 57.34 M, Net Income 6.112 M, EPS 0.0259

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change